← Back to Search

Crystalloid Fluids

Crystalloid Fluids for Cardiac Surgery Recovery

N/A

Waitlist Available

Led By Jean-François Cailhier, MD

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 48 hours

Awards & highlights

Study Summary

This trial will evaluate which of 3 fluids is best for cardiac surgery patients to reduce infection & renal failure.

Who is the study for?

This trial is for heart surgery patients who need coronary artery bypass with a machine that takes over for the heart and lungs during surgery. They can't join if they've had recent cancer treatments, are pregnant, have severe infections or immune issues, organ failure, certain blood disorders, hepatitis C or HIV.Check my eligibility

What is being tested?

The study is testing three types of IV fluids (Normal Saline, PlasmaLyte, Ringer's Lactate) in patients after heart surgery to see which one might lead to fewer infections and less kidney damage.See study design

What are the potential side effects?

While not directly mentioned, potential side effects from crystalloid fluid infusions could include electrolyte imbalances like too much or too little sodium or chloride in the blood.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 48 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~48 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in monocyte phenotype before and after cardiac surgery

Secondary outcome measures

Length of stay in intensive care unit after cardiac surgery

Sequential Organ Failure Assessment (SOFA) score after cardiac surgery

Trial Design

3Treatment groups

Experimental Treatment

Group I: Ringer's LactateExperimental Treatment1 Intervention

5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, Ringer's lactate as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.

Group II: PlasmaLyteExperimental Treatment1 Intervention

5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, PlasmaLyte as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.

Group III: Normal SalineExperimental Treatment1 Intervention

5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, Normal Saline as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor

366 Previous Clinical Trials

129,622 Total Patients Enrolled

4 Trials studying Postoperative Complications

1,046 Patients Enrolled for Postoperative Complications

Jean-François Cailhier, MDPrincipal InvestigatorCRCHUM

1 Previous Clinical Trials

14 Total Patients Enrolled

Media Library

Crystalloid fluid infusion (Crystalloid Fluids) Clinical Trial Eligibility Overview. Trial Name: NCT05834257 — N/A

Postoperative Complications Research Study Groups: Normal Saline, Ringer's Lactate, PlasmaLyte

Postoperative Complications Clinical Trial 2023: Crystalloid fluid infusion Highlights & Side Effects. Trial Name: NCT05834257 — N/A

Crystalloid fluid infusion (Crystalloid Fluids) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05834257 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment process for this clinical trial currently open?

"Correct. According to information on clinicaltrials.gov, this medical trial is actively accepting participants since its initial posting of March 31st 2023 and the most recent update on April 17th 2023. 15 patients are needed at one location for successful completion of the study."

Answered by AI

Are individuals aged 55 and over accepted into this research endeavor?

"This medical study is seeking participants who are over 65 and under 85 years old."

Answered by AI

What is the process for becoming part of this clinical trial?

"Requirements to be a part of this study include age between 65 and 85, as well as a diagnosis of postoperative complications. A limited number of 15 participants are available for enrollment."

Answered by AI

How many participants are being enrolled in this research endeavor?

"Indeed, the information available on clinicaltrials.gov states that this clinical trial is actively recruiting participants. It was first advertised on March 31st 2023 and updated most recently on April 17th of the same year. The research requires 15 volunteers from a single location to join in its efforts."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Crystalloid Fluids and Cardiac Surgery

2023. "Crystalloid Fluids and Cardiac Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05834257.